Overview

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Status:
RECRUITING

Trial end date:
2025-07-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

repotrectinib